Quantitative assessment of PTPN11 or RAS mutations at the neonatal period and during the clinical course in patients with juvenile myelomonocytic leukaemia

British Journal of Haematology

Volumn 148, Issue 4, 2010, Pages 593-599

  Matsuda, Kazuyuki ^a   Sakashita, Kazuo ^b   Taira, Chiaki ^a   Tanaka Yanagisawa, Miyuki ^b   Yanagisawa, Ryu ^b   Shiohara, Masaaki ^b   Kanegane, Hirokazu ^c   Hasegawa, Daiichiro ^d   Kawasaki, Keiichiro ^d   Endo, Mikiya ^e   Yajima, Shuhei ^f   Sasaki, Shinya ^g   Kato, Keisuke ^h   Koike, Kazutoshi ^h   Kikuchi, Akira ^i,j   Ogawa, Atsushi ^k   Watanabe, Akihiro ^k   Sotomatsu, Manabu ^l   Nonoyama, Shigeaki ^m   Koike, Kenichi ^b  

^a SHINSHU UNIVERSITY HOSPITAL   (Japan)

^b SHINSHU UNIVERSITY SCHOOL OF MEDICINE   (Japan)

^c UNIVERSITY OF TOYAMA   (Japan)

^d KOBE CHILDREN S HOSPITAL   (Japan)

^e IWATE MEDICAL UNIVERSITY   (Japan)

^f HAMAMATSU MEDICAL CENTER   (Japan)

^g HIROSAKI UNIVERSITY   (Japan)

^h Ibaraki Children's Hospital   (Japan)

ⁱ SAITAMA CHILDREN'S MEDICAL CENTER   (Japan)

^j UNIVERSITY OF TOKYO   (Japan)

^k NIIGATA CANCER CENTER HOSPITAL   (Japan)

^l Gumna Children S Medical Center   (Japan)

^m NATIONAL DEFENSE MEDICAL COLLEGE   (Japan)

more..

Author keywords

Allele specific quantitative PCR; Juvenile myelomonocytic leukaemia; Minimal residual disease; PTPN11; RAS

Indexed keywords

DNA; PROTEIN TYROSINE PHOSPHATASE SHP 2;

ARTICLE; CHILD; CLINICAL ARTICLE; CONTROLLED STUDY; DISEASE COURSE; FOLLOW UP; GENE MUTATION; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HUMAN; INFANT; JUVENILE MYELOMONOCYTIC LEUKEMIA; MINIMAL RESIDUAL DISEASE; NEWBORN PERIOD; ONCOGENE K RAS; ONCOGENE RAS; POLYMERASE CHAIN REACTION; PRESCHOOL CHILD; PRIORITY JOURNAL; SHORT TANDEM REPEAT; TUMOR VOLUME;

AGE FACTORS; DNA, NEOPLASM; FOLLOW-UP STUDIES; GENES, RAS; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HUMANS; INFANT, NEWBORN; LEUKEMIA, MYELOMONOCYTIC, JUVENILE; MUTATION; NEOPLASM, RESIDUAL; POLYMERASE CHAIN REACTION; PROTEIN TYROSINE PHOSPHATASE, NON-RECEPTOR TYPE 11;

EID: 75149143883     PISSN: 00071048     EISSN: 13652141     Source Type: Journal    
DOI: 10.1111/j.1365-2141.2009.07968.x     Document Type: Article

References (21)

1. Archambeault, S., Flores, N.J., Yoshimi, A., Kratz, C.P., Reising, M., Fischer, A., Noellke, P., Locatelli, F., Sedlacek, P., Flotho, C., Zecca, M., Emanuel, P.D., Castleberry, R.P., Niemeyer, C.M., Bader, P. Loh, M.L. (2008) Development of an allele-specific minimal residual disease assay for patients with juvenile myelomonocytic leukemia. Blood, 111, 1124 1127.
2. Candoni, A., Tiribelli, M., Toffoletti, E., Cilloni, D., Chiarvesio, A., Michelutti, A., Simeone, E., Pipan, C., Saglio, G. Fanin, R. (2009) Quantitative assessment of WT1 gene expression after allogeneic stem cell transplantation is a useful tool for monitoring minimal residual disease in acute myeloid leukemia. European Journal of Haematology, 82, 61 68.
3. Cha, R.S., Zarbl, H., Keohavong, P. Thilly, W.G. (1992) Mismatch amplification mutation assay (MAMA): application to the c-H-ras gene. PCR Methods and Applications, 2, 14 20.
4. Emanuel, P.D. (2008) Juvenile myelomonocytic leukemia and chronic myelomonocytic leukemia. Leukemia, 22, 1335 1342.
5. Flotho, C., Kratz, C.P., Bergsträsser, E., Hasle, H., Starý, J., Trebo, M., van den Heuvel-Eibrink, M.M., Wójcik, D., Zecca, M., Locatelli, F. Niemeyer, C.M. (2008) On behalf of the European Working Group of Myelodysplastic Syndromes in Childhood Genotype-phenotype correlation in cases of juvenile myelomonocytic leukemia with clonal RAS mutations. Blood, 111, 966 967.
6. Gale, K.B., Ford, A.M., Repp, R., Borkhardt, A., Keller, C., Eden, O.B. Greaves, M.F. (1997) Backtracking leukemia to birth: identification of clonotypic gene fusion sequences in neonatal blood spots. Proceedings of The National Academy of Sciences of the USA, 94, 13950 13954.
7. ®) and mismatch amplification mutation assay. Mutation Research, 430, 1 12.
8. Gruhn, B., Taub, J.W., Ge, Y., Beck, J.F., Zell, R., Häfer, R., Hermann, F.H., Debatin, K.M. Steinbach, D. (2008) Prenatal origin of childhood acute lymphoblastic leukemia, association with birth weight and hyperdiploidy. Leukemia, 22, 1692 1697.
9. Hämäläinen, M.M., Kairisto, V., Juvonen, V., Johansson, J., Aurén, J., Kohonen, K., Remes, K., Salmi, T.T., Helenius, H. Pelliniemi, T.T. (2008) Wilms tumour gene 1 overexpression in bone marrow as a marker for minimal residual disease in acute myeloid leukaemia. European Journal of Haematology, 80, 201 207.
10. Koldehoff, M., Steckel, N.K., Hlinka, M., Beelen, D.W. Elmaagacli, A.H. (2006) Quantitative analysis of chimerism after allogeneic stem cell transplantation by real-time polymerase chain reaction with single nucleotide polymorphisms, standard tandem repeats, and Y-chromosome-specific sequences. American Journal of Hematology, 81, 735 746.
11. Loh, M.L., Sakai, D.S., Flotho, C., Kang, M., Fliegauf, M., Archambeault, S., Mullighan, C.G., Chen, L., Bergstraesser, E., Bueso-Ramos, C.E., Emanuel, P.D., Hasle, H., Issa, J.P., van den Heuvel-Eibrink, M.M., Locatelli, F., Stary, J., Trebo, M., Wlodarski, M., Zecca, M., Shannon, K.M. Niemeyer, C.M. (2009) Mutations in CBL occur frequently in juvenile myelomonocytic leukemia. Blood, 114, 1859 1863.
12. Matsuda, K., Yamauchi, K., Tozuka, M., Suzuki, T., Sugano, M., Hidaka, E., Sano, K. Katsuyama, T. (2004) Monitoring of hematopoietic chimerism by short tandem repeats, and the effect of CD selection on its sensitivity. Clinical Chemistry, 50, 2411 2414.
13. Matsuda, K., Shimada, A., Yoshida, N., Ogawa, A., Watanabe, A., Yajima, S., Iizuka, S., Koike, K., Yanai, F., Kawasaki, K., Yanagimachi, M., Kikuchi, A., Ohtsuka, Y., Hidaka, E., Yamauchi, K., Tanaka, M., Yanagisawa, R., Nakazawa, Y., Shiohara, M., Manabe, A., Kojima, S. Koike, K. (2007a) Spontaneous improvement of hematologic abnormalities in patients having juvenile myelomonocytic leukemia with specific RAS mutations. Blood, 109, 5477 5480.
14. Matsuda, K., Nakazawa, Y., Sakashita, K., Shiohara, M., Yamauchi, K. Koike, K. (2007b) Acquisition of loss of the wild-type NRAS locus with aggressive disease progression in a patient with juvenile myelomonocytic leukemia and a heterozygous NRAS mutation. Haematologica, 92, 1576 1578.
15. Mizoguchi, Y., Fujita, N., Taki, T., Hayashi, Y. Hamamoto, K. (2009) Juvenile myelomonocytic leukemia with t(7;11)(p15;p15) and NUP98-HOXA11 fusion. American Journal of Hematology, 84, 295 297.
16. Newton, C.R., Graham, A., Heptinstall, L.E., Powell, S.J., Summers, C., Kalsheker, N., Smith, J.C. Markham, A.F. (1989) Analysis of any point mutation in DNA. The amplification refractory mutation system (ARMS). Nucleic Acids Research, 17, 2503 2516.
17. Nussenzveig, R.H., Swierczek, S.I., Jelinek, J., Gaikwad, A., Liu, E., Verstovsek, S., Prchal, J.F. Prchal, J.T. (2007) Polycythemia vera is not initiated by JAK2V617F mutation. Experimental Hematology, 35, 32 38.
18. Szczepański, T., Willemse, M.J., Brinkhof, B., van Wering, E.R., van der Burg, M. van Dongen, J.J. (2002) Comparative analysis of Ig and TCR gene rearrangements at diagnosis and at relapse of childhood precursor-B-ALL provides improved strategies for selection of stable PCR targets for monitoring of minimal residual disease. Blood, 99, 2315 2323.
19. van der Velden, V., Hochhaus, A., Cazzaniga, G., Szczepanski, T., Gabert, J. van Dongen, J.J. (2003) Detection of minimal residual disease in hematologic malignancies by real-time quantitative PCR: principles, approaches, and laboratory aspects. Leukemia, 17, 1013 1034.
20. Yoshida, N., Yagasaki, H., Xu, Y., Matsuda, K., Yoshimi, A., Takahashi, Y., Hama, A., Nishio, N., Muramatsu, H., Watanabe, N., Matsumoto, K., Kato, K., Ueyama, J., Inada, H., Goto, H., Yabe, M., Kudo, K., Mimaya, J., Kikuchi, A., Manabe, A., Koike, K. Kojima, S. (2009) Correlation of clinical features with the mutational status of GM-CSF signaling pathway-related genes in juvenile myelomonocytic leukemia. Pediatric Research, 65, 334 340.
21. Zhang, J., Wang, J., Liu, Y., Sidik, H., Young, K.H., Lodish, H.F. Fleming, M.D. (2009) Oncogenic Kras-induced leukemogeneis: hematopoietic stem cells as the initial target and lineage-specific progenitors as the potential targets for final leukemic transformation. Blood, 113, 1304 1314.